Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.
作者： Changhai Ding
DOI:
关键词: Rheumatoid arthritis 、 Drug 、 Clinical trial 、 Mitogen-activated protein kinase 、 Coronary disease 、 Pharmacology 、 Inflammation 、 Orally active 、 Medicine 、 Acute coronary syndrome
摘要: … by pre-incubation with 1 µM of VX-702 (IC50 = 4 to 20 nM). VX-702 had no effect on platelet … VX-702 did not directly cause platelet aggregation or induce Ca2+ mobilization, or affect …
utas.edu.au
researchgate.net 参考文章(8)
S KYOI, H OTANI, S MATSUHISA, Y AKITA, K TATSUMI, C ENOKI, H FUJIWARA, H IMAMURA, H KAMIHATA, T IWASAKA, Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster. Cardiovascular Research. ,vol. 69, pp. 888- 898 ,(2006) , 10.1016/J.CARDIORES.2005.11.015
SH Polmar, Chan-Loi Yong, Chester C Wood, Hildegrad Staehle, A Gupta, Safety and pharmacokinetics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered twice daily for 14 days to healthy volunteers The Journal of Allergy and Clinical Immunology. ,vol. 109, ,(2002) , 10.1016/S0091-6749(02)81293-3
John C Lee, Sanjay Kumar, Don E Griswold, David C Underwood, Bartholomew J Votta, Jerry L Adams, Inhibition of p38 MAP kinase as a therapeutic strategy Immunopharmacology. ,vol. 47, pp. 185- 201 ,(2000) , 10.1016/S0162-3109(00)00206-X
Masaki Suzuki, Toshifumi Tetsuka, Shinichi Yoshida, Nobuyuki Watanabe, Masaaki Kobayashi, Nobuo Matsui, Takashi Okamoto, The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-α- or IL-1β-stimulated rheumatoid synovial fibroblasts FEBS Letters. ,vol. 465, pp. 23- 27 ,(2000) , 10.1016/S0014-5793(99)01717-2
Xin L. Ma, Sanjay Kumar, Feng Gao, Calvert S. Louden, Bernard L. Lopez, Theodore A. Christopher, Chuanlin Wang, John C. Lee, Giora Z. Feuerstein, Tian-Li Yue, Inhibition of p38 Mitogen-Activated Protein Kinase Decreases Cardiomyocyte Apoptosis and Improves Cardiac Function After Myocardial Ischemia and Reperfusion Circulation. ,vol. 99, pp. 1685- 1691 ,(1999) , 10.1161/01.CIR.99.13.1685
Gabriel Mbalaviele, Gary Anderson, Amy Jones, Pamela De Ciechi, Steve Settle, Steve Mnich, Mark Thiede, Yousef Abu-Amer, Joseph Portanova, Joseph Monahan, Inhibition of p38 Mitogen-Activated Protein Kinase Prevents Inflammatory Bone Destruction Journal of Pharmacology and Experimental Therapeutics. ,vol. 317, pp. 1044- 1053 ,(2006) , 10.1124/JPET.105.100362
Satyanarayana Medicherla, Jing Ying Ma, Ruban Mangadu, Yebin Jiang, Jenny J. Zhao, Ramona Almirez, Irene Kerr, Elizabeth G. Stebbins, Gilbert O'Young, Ann M. Kapoun, Gregory Luedtke, Sarvajit Chakravarty, Sundeep Dugar, Harry K. Genant, Andrew A. Protter, A Selective p38α Mitogen-Activated Protein Kinase Inhibitor Reverses Cartilage and Bone Destruction in Mice with Collagen-Induced Arthritis Journal of Pharmacology and Experimental Therapeutics. ,vol. 318, pp. 132- 141 ,(2006) , 10.1124/JPET.105.098020
Christiane E Angermann, Christopher P Doe, Robert N Willette, Jeffrey Boehm, Haisong Ju, Marinela Berova, Thomas M Behr, p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease. Current opinion in investigational drugs. ,vol. 4, pp. 1059- ,(2003)